MENU
APR 02, 2020 8:30 AM PDT

Rapid Discovery of Therapeutic Antibodies for SARS-CoV-2 and Other Viral Pandemics

Sponsored by: Berkeley Lights
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Product Manager, Antibody Therapeutics, Berkeley Lights, Inc.
    Biography
      Anupam Singhal earned his PhD from the University of British Columbia and has over 15 years of experience in nanotechnology and microfluidics at UBC, the University of Toronto and Stanford University. His work has been cited over 600 times and resulted in several patents for molecular disease diagnosis, antibody discovery, and development of production cell-lines for biologics. At Berkeley Lights, Anupam leads the development of next-generation platforms for the discovery and development of antibody therapeutics.

    Abstract

    Humans are susceptible to many life-threatening viruses such as HIV, influenza and Ebola. The current coronavirus pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was recognized as a pandemic by the World Health Organization (WHO) on March 11, 2020.  Rapid discovery and development of new therapeutics is therefore an absolute necessity to combat these viruses.

    B cells from exposed patients are a potential source of viral neutralizing antibodies. We will demonstrate how B Cell Antibody Discovery on the Beacon® system can be used to rapidly screen human B cells to identify anti-viral antigen-specific antibodies in under a week.  B cells can be screened from both acute and convalescent patients. Our collaborators have already leveraged the speed of our platform to discover >500 antibodies to SARS-CoV-2 in a single day.

    This workflow has the potential to enable rapid discovery of antibodies against difficult therapeutic targets such as SARS-CoV-2 and other viruses.

    Learning Objectives:

    1. Rapid discovery of antibodies against SARS-CoV-2 and other pandemic viruses
    2. Screening of B cells to identify novel therapeutic antibodies
    3. Rapid down-selection of lead candidates

     

     


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 08, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    Loading Comments...
    Show Resources